Survey Or Shakedown? US Medicaid’s Audacious Negotiation Plan
Executive Summary
The US Medicaid program is proposing what amounts to a price negotiation program by using a survey/audit authority as a 'stick' to encourage manufacturers to offer supplemental rebates or outcomes-based contracts. Is it an offer sponsors can’t refuse?
You may also be interested in...
Value-Based Pricing Bill with New Protections for Medicare and Medicaid Clears House Panel
Energy and Commerce Committee made some changes to a Trump-era regulation designed to make it easier for manufacturers to enter into value-based drug pricing contracts with commercial payers to limit unintended consequences for Medicaid and Medicare, but most Democrats say the tweaks don’t outweigh the harms of codifying the regulation.
Medicaid ‘Price Verification’ Audit Proposal Aims To Promote Cell, Gene Therapy Rebate Concessions
CMS proposed rule impact may be ‘modest’ but is framed as ensuring patient access to cutting edge treatments by helping to control Medicaid spending. Biden administration initiative also aims to address misclassification of brand drugs, duplicative 340B discounts, and PBM spread pricing.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.